Precipio Inc
NASDAQ:PRPO
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Precipio Inc
NASDAQ:PRPO
|
42.3m USD |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
95.7B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
61.7B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
72.6B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27.4B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.3B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20.9B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.7B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.9B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Precipio Inc
Glance View
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in Omaha, Nebraska and currently employs 55 full-time employees. The company went IPO on 2000-07-18. The firm is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Precipio Inc is -5.5%, which is above its 3-year median of -39.8%.
Over the last 3 years, Precipio Inc’s Net Margin has increased from -128% to -5.5%. During this period, it reached a low of -129.6% on Dec 31, 2022 and a high of -5.5% on Sep 30, 2025.
